Cambridge, MA – Gensaic Inc. has announced the appointment of Nathan Higginson-Scott as Chief Research & Development Officer. About Gensaic Inc.: Gensaic combines AI-powered protein design with unbiased directed evolution to develop tissue-selective ligands for targeted intracellular therapeutic delivery. The company’s portfolio advances therapies for metabolic and age-related diseases, with an initial focus on siRNA payloads. FORGE, Gensaic’s proprietary product engine, integrates phage display for unbiased protein evolution within a generative AI architecture to discover and optimize protein molecules with enhanced tissue selectivity and drug-like properties. Founded through MIT and based in Cambridge, Massachusetts, Gensaic’s team of physicians, bioengineers, and machine learning scientists is advancing a singular objective: to enable selective delivery of any therapeutic payload to any tissue of interest.

For more information on Gensaic Inc. please visit: https://www.gensaic.com/

Website: https://www.gensaic.com/
LinkedIn Page: https://www.linkedin.com/company/gensaic/

Gensaic Inc.
238 Main St
Cambridge, MA 2142
Phone: 914-327-6361

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved